Market Closed -
Nasdaq
04:00:00 2024-05-10 pm EDT
|
5-day change
|
1st Jan Change
|
0.2766
USD
|
-7.74%
|
|
-5.31%
|
-91.36%
|
Fiscal Period: December |
2022
|
2023
|
2024
|
2025
|
---|
Capitalization
1 |
4.536
|
1.759
|
2.269
|
-
|
Enterprise Value (EV)
1 |
4.536
|
1.759
|
2.269
|
2.269
|
P/E ratio
|
-0.44
x
|
-
|
-0.24
x
|
-0.53
x
|
Yield
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
75.1
x
|
23.3
x
|
29.1
x
|
-
|
EV / Revenue
|
75.1
x
|
23.3
x
|
29.1
x
|
-
|
EV / EBITDA
|
-
|
-
|
-
|
-
|
EV / FCF
|
-
|
-
|
-
|
-
|
FCF Yield
|
-
|
-
|
-
|
-
|
Price to Book
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
489
|
550
|
8,204
|
-
|
Reference price
2 |
9.280
|
3.200
|
0.2766
|
0.2766
|
Announcement Date
|
2/27/23
|
2/21/24
|
-
|
-
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net sales
1 |
-
|
0.0604
|
0.0754
|
0.078
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-
|
-6.099
|
-4.876
|
-5.01
|
-
|
Operating Margin
|
-
|
-10,090.21%
|
-6,466.82%
|
-6,423.08%
|
-
|
Earnings before Tax (EBT)
1 |
-
|
-7.606
|
-4.911
|
-5.91
|
-5.169
|
Net income
1 |
-4.95
|
-7.606
|
-4.911
|
-5.91
|
-5.169
|
Net margin
|
-
|
-12,583.62%
|
-6,513.75%
|
-7,576.92%
|
-
|
EPS
2 |
-14.08
|
-20.96
|
-
|
-1.140
|
-0.5200
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/4/22
|
2/27/23
|
2/21/24
|
-
|
-
|
Fiscal Period: December |
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
|
0.0107
|
0.0182
|
0.0225
|
0.0255
|
0.0171
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
|
-2.365
|
-1.633
|
-1.327
|
-1.181
|
-1.406
|
-
|
-
|
-
|
-
|
-
|
Operating Margin
|
-22,147.94%
|
-8,964.11%
|
-5,891.47%
|
-4,637.85%
|
-8,237.84%
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-3.708
|
-1.633
|
-1.329
|
-1.183
|
-1.465
|
-
|
-1.708
|
-1.542
|
-1.412
|
-1.248
|
Net income
1 |
-3.836
|
-1.633
|
-1.329
|
-1.183
|
-1.465
|
-0.998
|
-1.708
|
-1.542
|
-1.412
|
-1.248
|
Net margin
|
-35,914.98%
|
-8,962.84%
|
-5,901.02%
|
-4,646.49%
|
-8,579.73%
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-7.840
|
-3.360
|
-1.600
|
-2.400
|
-2.880
|
-1.920
|
-0.5700
|
-0.2100
|
-0.1900
|
-0.1700
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
8/15/22
|
11/14/22
|
2/27/23
|
7/3/23
|
8/25/23
|
11/14/23
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
Capex
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/4/22
|
2/27/23
|
2/21/24
|
-
|
-
|
Last Close Price
0.2766
USD Average target price
1.5
USD Spread / Average Target +442.30% Consensus |
1st Jan change
|
Capi.
|
---|
| -91.36% | 2.27M | | +17.96% | 44.96B | | +48.77% | 41.85B | | +1.17% | 42.65B | | -4.27% | 29.04B | | +11.42% | 26.08B | | -21.39% | 19.03B | | +4.86% | 12.75B | | +27.29% | 12.06B | | -3.50% | 11.75B |
Other Biotechnology & Medical Research
|